



KAREN L. SMITH, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

OFFICE OF AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2016-01

Date: March 15, 2016

TO: LOCAL ADAP COORDINATORS
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF OMBITASVIR/PARITAPREVIR/RITONAVIR
(TECHNIVIE™) TO THE ADAP FORMULARY

Effective March 14, 2016, ombitasvir/paritaprevir/ritonavir (Technivie™) has been added to the ADAP formulary. Ombitasvir/paritaprevir/ritonavir was approved by the federal Food and Drug Administration (FDA) on July 24, 2015.

Ombitasvir/paritaprevir/ritonavir is a once-daily (two tablet) fixed-dose combination of paritaprevir 150mg, ritonavir 100mg and ombitasvir 25mg. This drug is to be used in combination with ribavirin for treatment of patients infected with genotype 4 hepatitis C virus (HCV) who do not present with cirrhosis. Ombitasvir/paritaprevir/ritonavir is the second FDA approved HCV drug treatment for individuals with genotype 4 HCV, the first being sofosbuvir (Sovaldi) which was previously added to the ADAP formulary.

With the addition of ombitasvir/paritaprevir/ritonavir, ADAP formulary consists of 196 drugs on the formulary, including those necessary to treat HIV in accordance with the federal treatment guidelines for HIV/AIDS and associated opportunistic infections.

If you have any questions regarding the addition of this drug to the ADAP formulary, please contact me at (916) 449-5942 or Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Niki Dhillon, Chief
ADAP Branch
Office of AIDS